NewEdge Advisors’s Definium Therapeutics DFTX Stock Holding History

NewEdge Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$222K	Buy	4,721 +4,714	+67,343%	+$116K	﹤0.01%	2700
2026 Q1	$125	Sell	7 -133	-95%	-$2.26K	﹤0.01%	4080
2025 Q4	$1.87K	Sell	140 -2	-1%	-$25	﹤0.01%	3896
2025 Q3	$1.67K	Hold	142	–	–	﹤0.01%	3812
2025 Q2	$921	Hold	142	–	–	﹤0.01%	3728
2025 Q1	$831	Sell	142 -6	-4%	-$43	﹤0.01%	3653
2024 Q4	$1.03K	Hold	148	–	–	﹤0.01%	3560
2024 Q3	$842	Hold	148	–	–	﹤0.01%	3543
2024 Q2	$1.07K	Hold	148	–	–	﹤0.01%	3459
2024 Q1	$1.39K	Hold	148	–	–	﹤0.01%	3443
2023 Q4	$542	Hold	148	–	–	﹤0.01%	3528
2023 Q3	$463	Hold	148	–	–	﹤0.01%	3263
2023 Q2	$528	Buy	148 +133	+887%	+$459	﹤0.01%	3311
2023 Q1	$48	Hold	15	–	–	﹤0.01%	3363
2022 Q4	$0	Buy	+15	New	+$42	﹤0.01%	4164

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NewEdge Advisors's DFTX Position: Q2 2026 in Review

NewEdge Advisors increased its Definium Therapeutics (DFTX) stake by 67,343% in Q2 2026, buying an estimated $116K and bringing the position to 4,721 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #2700.

NewEdge Advisors first reported a position in DFTX in Q4 2022 and has held it in 15 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

NewEdge Advisors held 4,721 shares of Definium Therapeutics worth $222K as of Q2 2026.
NewEdge Advisors bought 4,714 Definium Therapeutics shares in Q2 2026, an estimated $116K.
Definium Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2700 holding.
NewEdge Advisors first reported a position in Definium Therapeutics in Q4 2022 and has held it in 15 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.